Literature DB >> 29124429

What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection?

Masahiro Miyajima1, Atsushi Watanabe2, Toshihiko Sato3, Satoshi Teramukai4, Masahito Ebina5, Kazuma Kishi6, Yukihiko Sugiyama7, Haruhiko Kondo8, Satoru Kobayashi9, Yutaka Takahashi10, Hiroyuki Ito11, Ryoji Yamamoto12, Shigeki Sawada13, Hideki Fujimori14, Kazunori Okabe15, Jun Arikura16, Yasushi Shintani17, Hiroshige Nakamura18, Shinichi Toyooka19, Tohru Hasumi20, Takehiro Watanabe21, Yoshinobu Hata22, Hisashi Iwata23, Minoru Aoki24, Kazuhito Funai25, Shuhei Inoue26, Osamu Kawashima27, Tomohiko Iida28, Hiroshi Date3.   

Abstract

PURPOSES: Acute exacerbation of interstitial pneumonia (AEIP) is a leading cause of death after lung cancer resection in patients with interstitial lung disease.
METHODS: We retrospectively analyzed 1763 patients with non-small cell lung cancer with a clinical diagnosis of interstitial lung disease (ILD) who underwent lung cancer resection between 2000 and 2009 at 61 hospitals in Japan. AEIP occurred in 164 of 1763 (9.3%) patients with a mortality rate of 43.9% (72/164). Univariate and multivariate analyses were carried out to identify possible risk factors of fatal AEIP. We then analyzed the 164 patients who developed postoperative AEIP and identified the preoperative and postoperative risk factors.
RESULTS: A multivariate regression analysis identified that the sex, percent vital capacity, neoadjuvant radiation, preoperative history of AEIP, preoperative use of steroids, usual interstitial pneumonia pattern on CT, and surgical procedures were independent preoperative risk factors for death due to AEIP. ILD patients with emphysema somehow showed a lower risk of fatal AEIP than those without emphysema in this study.
CONCLUSIONS: This study revealed eight risk factors for fatal AEIP.

Entities:  

Keywords:  Acute exacerbation of interstitial pneumonia; Idiopathic interstitial pneumonia; Neoadjuvant chemotherapy; Primary lung cancer; Sialylated carbohydrate antigen KL-6

Mesh:

Year:  2017        PMID: 29124429     DOI: 10.1007/s00595-017-1605-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  36 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Authors:  Hiroshi Ohnishi; Akihito Yokoyama; Keiichi Kondo; Hironobu Hamada; Masahiro Abe; Kazutaka Nishimura; Kunio Hiwada; Nobuoki Kohno
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

3.  Pirfenidone in idiopathic pulmonary fibrosis.

Authors:  H Taniguchi; M Ebina; Y Kondoh; T Ogura; A Azuma; M Suga; Y Taguchi; H Takahashi; K Nakata; A Sato; M Takeuchi; G Raghu; S Kudoh; T Nukiwa
Journal:  Eur Respir J       Date:  2009-12-08       Impact factor: 16.671

4.  Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure.

Authors:  J B Stern; H Mal; O Groussard; O Brugière; A Marceau; G Jebrak; M Fournier
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

5.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

6.  Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.

Authors:  Takekazu Iwata; Shigetoshi Yoshida; Kaoru Nagato; Takahiro Nakajima; Hidemi Suzuki; Tetsuzo Tagawa; Teruaki Mizobuchi; Satoshi Ota; Yukio Nakatani; Ichiro Yoshino
Journal:  Surg Today       Date:  2014-11-22       Impact factor: 2.549

Review 7.  Corticosteroids for idiopathic pulmonary fibrosis.

Authors:  L Richeldi; H R Davies; G Ferrara; F Franco
Journal:  Cochrane Database Syst Rev       Date:  2003

8.  Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.

Authors:  Christopher J Ryerson; Thomas Hartman; Brett M Elicker; Brett Ley; Joyce S Lee; Marta Abbritti; Kirk D Jones; Talmadge E King; Jay Ryu; Harold R Collard
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

9.  Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer.

Authors:  Toshihiko Sato; Satoshi Teramukai; Haruhiko Kondo; Atsushi Watanabe; Masahito Ebina; Kazuma Kishi; Yoshitaka Fujii; Tetsuya Mitsudomi; Masahiro Yoshimura; Tomohiro Maniwa; Kenji Suzuki; Kazuhiko Kataoka; Yukihiko Sugiyama; Takashi Kondo; Hiroshi Date
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-20       Impact factor: 5.209

10.  Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis.

Authors:  Tomoo Kishaba; Hitoshi Tamaki; Yousuke Shimaoka; Hajime Fukuyama; Shin Yamashiro
Journal:  Lung       Date:  2013-11-13       Impact factor: 2.584

View more
  3 in total

1.  Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease.

Authors:  Yasuhito Hagiwara; Yuko Nakayama; Shigehiro Kudo; Toyokazu Hayakawa; Naoki Nakamura; Yoshizumi Kitamoto; Shigeo Takahashi; Kayoko Tsujino; Nobuteru Kubo; Yukihisa Tamaki; Yasushi Nagata
Journal:  J Radiat Res       Date:  2020-07-06       Impact factor: 2.724

2.  Pulmonary Rehabilitation of a Case With Worsening Dyspnea Due to Acute Exacerbation of Interstitial Pneumonia After Video-Assisted Thoracic Surgery.

Authors:  Kohji Iwai; Jun Hanaoka
Journal:  Cureus       Date:  2022-02-23

Review 3.  Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges.

Authors:  Namrata Kewalramani; Carlos Machahua; Venerino Poletti; Jacques Cadranel; Athol U Wells; Manuela Funke-Chambour
Journal:  ERJ Open Res       Date:  2022-06-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.